| http://www.cninfo.com.cn/new/disclosure/detail?stockCode=301563&announcementId=122472 | 301563 | 云汉芯城 | 8065&orgId=9900048908&announcementTime=2025 | -10-23 | | | --- | --- | --- | --- | --- | --- | | http://www.cninfo.com.cn/new/disclosure/detail?stockCode=600708&announcementId=122472 | 600708 | 光明地产 | 6586&orgId=gssh0600708&announcementTime=2025 | -10-23 | | | http://www.cninfo.com.cn/new/disclosure/detail?stockCode=605580&announcementId=122472 | 605580 | 恒盛能源 | 6432&orgId=gfbj0872062&announcementTime=2 ...

Core Viewpoint - Guangji Pharmaceutical's stock has shown fluctuations in recent trading, with a year-to-date increase of 10.19% but a recent decline over the past five days of 2.44% [1][2] Financial Performance - For the period from January to September 2025, Guangji Pharmaceutical reported revenue of 429 million yuan, a year-on-year decrease of 7.12%, while the net profit attributable to shareholders was -97.30 million yuan, an increase of 38.64% year-on-year [2][3] - The company has cumulatively distributed 132 million yuan in dividends since its A-share listing, with no dividends distributed in the past three years [3] Stock Market Activity - As of October 31, Guangji Pharmaceutical's stock price was 6.81 yuan per share, with a market capitalization of 2.36 billion yuan [1] - The stock has appeared on the "Dragon and Tiger List" three times this year, with the most recent appearance on October 24, where it recorded a net buy of -2.12 million yuan [1] Shareholder Information - As of September 30, 2025, the number of shareholders was 24,200, a decrease of 5.13% from the previous period, with an average of 14,221 circulating shares per shareholder, an increase of 5.41% [2] - Notable institutional holdings include Huaxia CSI 500 Index Enhanced A and Jinyuan Shun'an Yuanqi Flexible Allocation Mixed Fund, with the former being a new shareholder [3]

Core Viewpoint - Guangji Pharmaceutical (000952) announced that neither the company nor its controlling subsidiaries have any external guarantees, overdue guarantees, or any litigation related to external guarantees, nor have they incurred losses due to being ruled against in guarantee-related cases [1] Summary by Category - **Company Guarantees** - The company has confirmed that there are no external guarantees in place [1] - There are no overdue guarantees reported [1] - **Litigation and Legal Matters** - The company is not involved in any litigation related to external guarantees [1] - There have been no losses incurred from being ruled against in guarantee-related cases [1]

湖北广济药业股份有限公司（以下简称"广济药业"或"公司"）于 2025 年 10 月 29 日召开第十一届董事会第十二次（临时）会议，审议通过了《关于拟为控股子公司广 济药业（孟州）有限公司提供担保的议案》，同意公司为控股子公司广济药业（孟州） 有限公司（以下简称"孟州公司"）开展的借款业务提供担保，具体情况如下： 一、担保情况概述 为了保障孟州公司生产经营所需流动资金，孟州公司拟向中信银行股份有限公司 （以下简称"中信银行"）申请人民币 2,000 万元、借款年利率不超过 4%、期限 15 个 月的授信额度。授信用途为日常经营周转，由孟州公司位于孟州市西虢镇汶水路 81 号 不动产（不动产证号：豫(2017)孟州市不动产权第 0000753 号）提供抵押担保。 证券代码：000952 证券简称：广济药业 公告编号：2025-056 湖北广济药业股份有限公司 关于拟为控股子公司广济药业（孟州）有限公司 提供担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 广济药业拟对上述业务项下的全部债权提供连带责任保证担保，具体担保期限、额 度以公司与中信银行签署 ...

证券代码：000952 证券简称：广济药业 公告编号：2025-055 湖北广济药业股份有限公司 关于公司向银行申请综合授信额度的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 湖北广济药业股份有限公司（以下简称"广济药业"或"公司"）于 2025 年 10 月 29 日召开第十一届董事会第十二次（临时）会议，审议通过了《关于公司向银行申请综 合授信额度的议案》，具体情况如下： 一、申请综合授信情况 根据生产经营和业务发展需要，公司拟向中国民生银行股份有限公司武汉分行申请 综合授信 15,000 万元，授信期限 1 年（其中中长期流动资金贷款支用额度不超过 1 亿 元，期限不超过 2 年），授信品种为流动资金贷款、银行承兑汇票、银承贴现、国内信 用证、信融 e 等，担保方式为抵押（以公司位于武穴市大金镇张榜村宋煜村刘元村大金 产业园及大金镇武梅路东土地面积 712,063.09 平方米、建筑面积总计 79,354.17 平方 米的土地使用权及不动产抵押权证），年利率不超过 3%。 以上授信额度不等于公司的实际融资金额，实际融资金额及资产抵押情况由公司视 ...

证券代码：000952 证券简称：广济药业 公告编号：2025-054 湖北广济药业股份有限公司 第十一届董事会第十二次（临时）会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、董事会会议召开情况 1、会议通知的时间和方式：会议通知于 2025 年 10 月 20 日以专人送达、书 面传真和电子邮件形式发出； 2、会议的时间和方式：2025 年 10 月 29 日上午 10 点以通讯的方式召开； 3、本次会议应参与表决董事 9 人（含独立董事 3 人），实际参与表决董事 9 人。其中，董事长胡立刚先生因公务原因不能亲自出席本次会议，已授权董事 龚铖先生代为出席并行使表决权。经全体过半数董事推举，由董事龚铖先生代董 事长胡立刚先生主持本次会议； 4、本次会议由董事龚铖先生主持； 表决结果：9 票同意，0 票反对，0 票弃权，议案获得通过。 本议案已经公司第十一届董事会第七次独立董事专门会议审议通过，同意将 该议案提交本次董事会审议。 具体内容详见公司同日在指定媒体上披露的《关于拟为控股子公司广济药业 （孟州）有限公司提供担保的公告》（公告编号：2 ...

Core Viewpoint - Guangji Pharmaceutical (000952.SZ) reported a decline in revenue and significant losses in the third quarter of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company achieved a revenue of 429 million yuan in the first three quarters, representing a year-on-year decrease of 7.12% [1] - The net profit attributable to the parent company was a loss of 97.3 million yuan [1] - The non-recurring net profit also showed a loss of 101 million yuan [1] - The basic earnings per share were reported at -0.2789 yuan [1]

Core Viewpoint - Guangji Pharmaceutical reported a decline in revenue and a net loss for the third quarter of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company achieved an operating income of 145 million yuan in the third quarter of 2025, representing a year-on-year decrease of 12.57% [1] - The net profit attributable to shareholders was a loss of 21.7836 million yuan [1] - The basic earnings per share were reported at -0.0628 yuan [1]

Company Performance - Guangji Pharmaceutical reported a revenue of approximately 429 million yuan for the first three quarters of 2025, representing a year-on-year decrease of 7.12% [1] - The net profit attributable to shareholders of the listed company was a loss of approximately 97.3 million yuan [1] - The basic earnings per share showed a loss of 0.2789 yuan [1] Market Capitalization - As of the report, Guangji Pharmaceutical's market capitalization stands at 2.4 billion yuan [1]

证券代码：000952 证券简称：广济药业 公告编号：2025-052 湖北广济药业股份有限公司 第十一届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 表决结果：9 票同意，0 票反对，0 票弃权获得通过。 本议案已经公司第十一届董事会第六次审计委员会审议通过，同意将该议案 提交本次董事会审议。 1、会议通知的时间和方式：会议通知于 2025 年 10 月 13 日以专人送达、书 面传真和电子邮件形式发出； 2、会议的时间和方式：2025 年 10 月 23 日上午 10 点在湖北广济药业股份 有限公司（以下简称"公司"）武穴市大金产业园行政楼二楼会议室以现场结合 通讯的方式召开； 3、本次会议应到董事 9 人（含独立董事 3 人），实到董事 9 人，胡立刚先 生、龚铖先生、郭韶智先生、方智先生为现场表决，刘波先生、石守东先生、郭 炜先生、洪葵女士、梅建明先生为通讯表决； 4、本次会议由董事长胡立刚先生主持，全体高级管理人员列席本次会议； 5、本次会议的召开符合《中华人民共和国公司法》和《公司章程》的有关 规定，会议决议合法、有效 ...